Remacemide hydrochloride is a low-affinity, non-competitive NMDA receptor channel blocker under investigation for the treatment of epilepsy.
INTRODUCTION
Remacemide hydrochloride is a new antiepileptic drug (AED) with a novel mechanism of action. Remacemide and its principal active desglycinyl metabolite, are low affinity, non-competitive N -methyl-D-aspartic acid (NMDA) receptor channel blocking agents with additional significant sodium fast channel blocking activity 1 . This study was designed to establish an active dose range for remacemide hydrochloride in a B.I.D. regimen, as adjunctive therapy, in refractory patients with epilepsy receiving hepatic enzyme inducing AEDs. Early studies have shown that plasma concentrations of remacemide and its desglycinyl metabolite are reduced in the presence of hepatic enzyme-inducing drugs such as CBZ and PHT 2, 3 . In turn, interaction studies have shown that remacemide increases plasma concentrations of CBZ 3 and PHT 4 by inhibiting their metabolism. Plasma concentrations of CBZ and PHT were maintained within pre-determined limits by adjusting the dose of these drugs, as necessary, on an individual patient basis. 
MATERIALS AND METHODS
The study was approved by the appropriate ethics committee at each centre. All patients gave informed consent before study entry and the study was conducted in accordance with the Declaration of Helsinki. Patients were recruited at 26 centres in Canada, Australia and Germany. The first patient entered the study in November 1993 and the last patient completed in November 1995.
Study population
Male and female patients aged between 18 and 70 years, who had been diagnosed with epilepsy for at least one year and who were refractory to conventional therapies, were enrolled. Each patient was taking up to three AEDs, including at least one hepatic enzyme inducing drug (CBZ, PHT, phenobarbital or primidone). To enter the double-blind phase, patients had to have an average seizure frequency of at least four seizures per month during baseline. Patients were excluded if they had other significant medical history or a history of pseudoseizures. Women of childbearing potential were excluded unless, in the opinion of the investigator, they were reliable users of an effective contraceptive method.
A total of 240 patients were planned to complete the study (60 in each of four treatment groups). Assuming that 10% of patients in the placebo group would respond to treatment (response to treatment defined as a 50% or greater reduction in seizure frequency when compared with baseline), this sample size allowed the detection of a true difference of 23% or greater between the active treatment groups and placebo, based on two-tailed statistical tests with a 5% level of significance and 80% power.
Study design
The study design is shown in Fig. 1 . Patients who were taking CBZ or PHT had a 2-to 6-week run-in period, during which the investigator established each patient on an optimum regimen of CBZ or PHT. At the end of the run-in period, patients entered an 8-week baseline period during which their optimal dose was maintained and they were assessed every 2 weeks and provided blood samples for measurement of CBZ or PHT. These results were used in conjunction with a Shewhart control chart 5 to define a 'target range' for CBZ or PHT concentration for each patient. During the baseline period, patients continued to take the dose of CBZ or PHT on which they were stabilized.
After baseline, patients entered the double-blind period and were randomized to receive either placebo or one of three doses of remacemide hydrochloride (300, 600 or 800 mg/day) in a twice-daily regimen for 14 weeks. All patients randomized to active treatment received 300 mg/day during the first week. During the second week, patients randomized to the 600 and 800 mg/day groups received 600 mg/day. At the end of the second week, patients randomized to the 800 mg/day group were titrated up to 800 mg/day. By the end of the third week, all patients had reached their allocated dose. During the next 3 weeks, the investigator adjusted each patient's dose of CBZ or PHT, if necessary, until plasma concentrations were stable and within the target range. At the end of the dose titration phase (6 weeks in total), patients continued to receive study treatment for the remaining eight weeks of the double-blind period (the continuation phase). Patients who could not tolerate their allocated dose received a dose reduction and continued in the study.
At the end of the double-blind period, patients chose either to discontinue treatment or to enter an open-label extension study. For patients who chose to withdraw, study treatment was withdrawn gradually over 12 days to reduce the theoretical risk of rebound seizure activity. Patients who chose to continue treatment entered a 4-week double-blind transition period, during which the dose of remacemide was adjusted gradually so that all patients entered an open long-term extension study on a dose of 800 mg/day (patients who could not tolerate the 800 mg/day dose could enter the extension study on a dose of 600 mg/day).
Each day throughout the study, patients recorded adverse events, seizure type and frequency on a diary card. At each clinic visit, safety was assessed by clinical examination, electrocardiogram (ECG) and routine laboratory tests. Blood samples were taken at the end of the baseline period and throughout the double-blind period for measurements of plasma concentrations of remacemide and its desglycinyl metabolite. Blood samples were taken for measurement of other AEDs, as appropriate.
Outcome measures
The primary outcome measure was the percentage of patients who responded to treatment, i.e. who had a 50% or greater reduction in seizure frequency compared with baseline. An additional efficacy measure was the median percentage reduction in monthly seizure frequency.
The safety variables were adverse events, haematology and biochemistry, urinalysis, ECGs and vital signs.
Statistical analysis
The null hypothesis was that placebo and remacemide were equivalent. The analysis plan specified that the efficacy analyses would be based on all patients who completed at least 14 days of study treatment following the titration period. The number of responders (i.e.
≥50% reduction in seizure frequency) was compared using a chi-square test. Pairwise comparisons between groups were also carried out, again using a chisquare test. The Kruskal-Wallis test 6 was used to compare each of the other efficacy variables between treatments. All randomized patients were included in the safety analyses. Analysis of variance was used to compare treatment groups for laboratory variables, ECG parameters and vital signs.
An adjustment was made for centre in most analyses. Data from each time point was analysed separately using analysis of variance with treatment, centre and treatment-by-centre interactions as factors. No adjustment was made for multiple testing.
RESULTS

Patient characteristics
The four treatment groups were similar with respect to age, height and weight but there was a difference in the male:female ratio in the placebo and 300 mg groups. The majority of patients were white (95%). The other races were evenly distributed among the treatment groups. Patient demographics are summarized in Table 1 . Table 1 : Patient characteristics (mean ± SD).
Placebo 300 mg 600 mg 800 mg n = 64 n = 66 n = 64 n = 68
Age (years) 37.8 ± 11.0 37.6 ± 9.6 36.7 ± 9.6 34.4 ± 11.5 Height (cm) 172.5 ± 9.7 167.7 ± 9.6 168.0 ± 11.0 168.6 ± 11.0 Weight (kg) 80. Table 2 shows the number of AEDs taken by each patient at entry; the majority (61%) were taking two AEDs. Overall, the most frequently taken AEDs were; CBZ, PHT, sodium valproate and clobazam. The mean duration of epilepsy was similar in each treatment group (between 24 and 28 years) and aetiology was most frequently recorded as idiopathic. These details are shown in Table 3 . In all four treatment groups, complex partial seizures were the most common seizure. Only two patients had seizures which were unclassified. Table 4 summarizes patients' seizure classification; many patients recorded more than one type of seizure. 
Disposition of patients
A total of 262 patients were randomized and received study treatment, with 232 completing the double-blind period. The numbers of patients at each stage of the study are shown in Fig. 2 . Patient withdrawals during the double-blind treatment period are summarized in Table 5 . There were more withdrawals due to adverse events in the 600 and 800 mg/day groups than in the 300 mg/day and placebo groups during the double-blind period. All 262 patients who received treatment were included in the safety analyses. A total of 237 patients completed at least 14 days' treatment following the titration phase and were included in the efficacy analysis; five of these patients withdrew before completing the double-blind period. 
Efficacy results
Responder rate Figure 3 shows the dose-related increase in the percentage of patients with a reduction of at least 50% in seizure frequency between baseline and continuation phase. Responder rates are also shown in Table 6 . The responder rate was 15% (9/60) of patients in the placebo group and 30% (18/60) of patients in the remacemide hydrochloride 800 mg/day group. Although there was no statistically significant difference among treatments overall (P = 0.208), a pairwise comparison between 800 mg/day and placebo was statistically significant in favour of remacemide hydrochloride (P = 0.049). Four patients became seizure-free during the study, two in the placebo group, one in the 600 mg/day group and one in the 800 mg/day group.
In a subsequent analysis, the proportion of patients whose seizure frequencies increased by at least 100% was found to be 3% in the placebo group, 2% in the 300 mg/day group, 4% in the 600 mg/day group and 0% in the 800 mg/day group. Figure 4 shows that the median monthly seizure frequency decreased in all four groups over the course of the study. The largest median percentage change from baseline was in the remacemide hydrochloride 800 mg/day group (decrease of 31.4%), with the smallest median change in the placebo group (decrease of 10.1%). However, due to large variability, this trend did not reach statistical significance (P = 0.110).
Seizure frequency
Safety results
Adverse events
There was a dose-dependent increase in the percentage of patients reporting adverse events during the continuation phase: from 59% (36 patients) in the placebo group, to 78% (47 patients) in the 800 mg/day group. Most events were mild to moderate in severity and resolved without further treatment or discontinuation of study drug. The most frequently occurring adverse event during study treatment was headache, but this occurred to a similar extent in all the treatment groups. Table 7 summarizes the adverse events that were reported by five or more patients in any treatment group. During the double-blind period, three patients in the placebo group reported five serious events and 18 patients in the three remacemide treatment groups reported 18 serious events. Ten events (all in the remacemide groups) were considered by the investigator to be possibly related to treatment; five of these were hospitalizations for aggravated seizures. Two patients had a range of central nervous system (CNS), and visual disorder symptoms and one patient had a range of psychiatric symptoms. The other events were gastritis (one patient) and raised liver enzymes (one patient).
A total of 21 patients were withdrawn from doubleblind treatment due to adverse events. Table 5 summarises patient withdrawals. Adverse events leading to withdrawal were mainly CNS or gastrointestinalrelated.
Other safety assessments
Details of the few patients who developed laboratory abnormalities during the study are summarized in Table 8 . There were no clinically significant trends Treatment Group to suggest that any biochemical abnormalities were related to treatment with remacemide hydrochloride. Similarly, there were no clinically significant differences between the groups for changes in ECG parameters or vital signs.
Carbamazepine and phenytoin control
Plasma levels of CBZ and PHT were well controlled during the study. Mean levels of both drugs increased slightly following administration of remacemide hydrochloride. These changes are illustrated in Figs 5 and 6. In the case of CBZ, increases in plasma concentration were independent of the dose of remacemide hydrochloride, and the mean CBZ change was similar in responders and non-responders. For PHT there was wide variation in plasma concentrations in all treatment groups. There was no correlation between the percentage reduction in seizure frequency and plasma concentration of either CBZ or PHT.
Pharmacokinetics of remacemide and its desglycinyl metabolite
Despite considerable variability across treatment groups, plasma concentrations of remacemide and its desglycinyl metabolite were approximately proportional to dose. Steady-state plasma concentrations for each one hour period over the dosing interval, for the parent drug and metabolite, are illustrated in 
DISCUSSION
Assessment based on the key efficacy variable, responder rate, showed that remacemide hydrochloride 800 mg/day in a twice-daily regimen was significantly better than placebo at halving the number of seizures. The responder rate of 30% in the remacemide 800 mg/day group was similar to results for other AEDs 7 , but the responder rate in the placebo group (15%) was higher than expected. Few patients became seizure free but this was not unexpected in such a highly refractory population. Although the median percentage change in seizure frequency was not statistically significantly different among the treatment groups, the reduction in the 800 mg/day group (26%) was over three times greater than that in the placebo group (8%). Subsequent analysis has shown that the large variation in seizure frequency was not due to worsening of seizures in a proportion of patients.
Optimized plasma concentrations of CBZ and PHT were maintained successfully by regular monitoring and dose adjustments. There was no correlation between the concentration of either drug and the reductions in seizures, indicating that the improvements seen were not due to increases in CBZ or PHT levels.
The incidence of adverse events in this study was reflective of the population. Almost half of the patients (46%) reported adverse events during baseline, before taking study medication. The adverse event profile of remacemide was consistent with that from other studies in a similar patient population. CNS-related adverse events, such as those seen with remacemide hydrochloride in this study, are common to the majority of AEDs 8 .
The incidence of serious adverse events was no greater in the active treatment groups than in the placebo group and was no greater during double-blind treatment than during baseline.
The laboratory, ECG and vital sign measurements showed no significant changes with remacemide hydrochloride treatment.
In conclusion, there was a dose-dependent increase in the number of patients who had a ≥50% reduction in seizure frequency following treatment with remacemide hydrochloride compared with placebo; this reached statistical significance at the highest dose tested (800 mg/day). Remacemide hydrochloride doses of 300 and 600 mg/day appeared to be sub-optimal for hepatic enzyme-induced patients in this study.
Remacemide hydrochloride appeared to be generally well tolerated, with few serious adverse events and few withdrawals due to adverse events. Adverse events which appeared to distinguish remacemide hydrochloride from placebo were CNS and gastrointestinal-related.
Plasma concentrations of remacemide and the desglycinyl metabolite were variable following a particular dose but were broadly proportional to dose. Plasma concentrations of carbamazepine and phenytoin were successfully maintained within 'target' ranges for each individual.
